



www.3sbio.com

Cherish Life

Create Life

Care for Life



2009 Fourth Quarter and Full Year Results Presentation

February 12, 2010



Safe Harbor

Safe Harbor Statement:

Certain statements in the disclosures of 3SBio, Inc. (the “Company” or “3SBio”) for the fourth quarter of fiscal 2009 (“Disclosures”) that are not purely historical in nature may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Disclosures include the press release, the conference call and any accompanying materials, and any other information issued, released or publicized by the Company with respect to the fourth quarter of fiscal 2009.

These forward-looking statements address activities, events, conditions, or developments that we currently expect or anticipate may occur in the future, and include, but may not be limited to, discussions and statements regarding revenue guidance, product development, timing of plant construction completion, testing and certification, impact of the government policies and regulations, regulatory approval process, production capacity, capital expense estimate, future operations, investment portfolio management, and future strategies. Forward-looking statements can be identified by such terminology as “believe,” “expect,” “plans,” “strategy,” “potential,” “prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,” “will” or “would”, “may” or “might”, and words, phrases, expressions, and usages of similar meaning or substance or the negative of such words, phrases, expressions and usages.

Forward-looking statements are based on management’s current assumptions, beliefs, expectations, and projections, in light of the information currently available to it, and actual results, performances, or achievements could differ materially from those implied or expressed by the forward-looking statements. Among the factors that could cause 3SBio’s actual results to differ from what the Company currently anticipates may include competition from other domestic and foreign pharmaceutical companies; the expected market growth for pharmaceutical products in China; market acceptance of 3SBio products; expected hospital or patient demand for our products; the completion of 3SBio’s ongoing clinical trials as planned; receipt and timing of regulatory approvals for 3SBio’s new products and uses; 3SBio’s ability to expand its production, sales and distribution network and other aspects of its operations; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China.

For additional information on factors identified above and other risk factors, uncertainties and assumptions that may affect 3SBio’s business, financial conditions and results of operations, please refer to the Company’s filings with the Securities and Exchange Commission at www.sec.gov, and, in particular, “Introduction – Cautionary Statement concerning Forward Looking Statements”, Item 3.D “Risk Factors”, Item 5. “Operating and Financial Review and Prospects”, and other applicable discussions in 3SBio’s annual report on Form 20-F for the year ended December 31, 2008.

All the statements in the Disclosures speak as of the date of the initial release, even if subsequently made available on the 3SBio website or otherwise. 3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, subsequent events or otherwise, after the date of this press release.



www.3sbio.com

Cherish Life

Create Life

Care for Life



2009 Fourth Quarter


OVERVIEW



Providing World Class Care for China's Future

3SBio Inc. is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.

- ❖ Therapeutic focus on oncology and nephrology.
- ❖ 5 marketed products and 8 pipeline products under development.
 - EPIAO, the Company's flagship product, has been the No.1 EPO product in the Chinese market since 2002. (*source: IMS Health*)
 - TPIAO, the first protein-based TPO therapeutic product approved in the Chinese market.
 - Multiple late-stage development programs.
 - Strategic alliances offer innovative product development platforms





2009 Company Highlights

Solid Revenue Growth Led by EPIAO and TPIAO Products

- Substantial increase across entire product line**
- Growing dialysis market and oncology penetration**

Strong Bottom Line Financial Performance

- Operating margin improvement & positive cash flow**
- Strong balance sheet with over US\$100 million in cash**

Achieved 2009 Financial and Operational Objectives

- Submitted applications for Feraheme registration trial and NuPIAO Phase I clinical trial**
- Close cooperation with SFDA for approval of 3 phase III products submissions**
- Completed construction of new EPIAO/TPIAO plant**
- New partnerships provide access to innovative development platform and enhance product development pipeline**



www.3sbio.com

Cherish Life

Create Life

Care for Life



2009 Fourth Quarter

FINANCIAL HIGHLIGHTS



2010 Objectives

- **2010 full year revenue target US\$56-58 million, approximately 20-25% growth**
- **Initiate Feraheme registration trial in China, pending SFDA approval.**
- **Continue to work with the SFDA to secure regulatory approval of the three new product programs: 36,000 IU dosage formulation of EPIAO, Nuleusin and TPIAO label extension for the treatment of ITP.**
- **Complete validation of the new plant and obtain GMP certification from the SFDA.**
- **Explore global biosimilar opportunities and initiate the approval process in selected developed markets.**
- **Continue to pursue external strategic partnerships that leverage our balance sheet and strong nephrology and oncology franchises.**



Highlights For Fourth Quarter 2009 (GAAP)

<i>(GAAP, expressed in millions, except per ADS data.)</i>	For the three months ended Dec 31, 2008 <i>(unaudited) RMB</i>	For the three months ended Dec 31, 2009		YoY Inc/dec %
		<i>(unaudited) RMB</i>	<i>(unaudited) US\$</i>	
Net revenues:	60,064	74,276	10,881	23.7%
Gross profit	54,442	68,030	9,966	25.0%
<i>Gross profit margin</i>	<i>90.6%</i>	<i>91.6%</i>	<i>91.6%</i>	<i>1.0%</i>
Operating expenses	56,736	58,097	8,511	2.4%
Operating income	(2,294)	9,933	1,455	-533.0%
<i>Operating margin</i>	<i>-3.8%</i>	<i>13.4%</i>	<i>13.4%</i>	<i>17.2%</i>
Net income attributable to the equity holders of the parent	(1,458)	13,650	2,000	-1036.2%
Net income per ADS attributable to the equity holders of the parent <i>Basic and diluted</i>	(0.07)	0.63	0.09	-1000.0%

Note: YoY changes are based on RMB values.



Financial Summary (GAAP)

1Q - 4Q 2009

Highlights For Full Year 2009 (GAAP)

<i>(GAAP, expressed in millions, except per ADS data.)</i>	For the full year ended Dec 31, 2008 <i>(audited) RMB</i>	For the full year ended Dec 31, 2009		YoY Inc/dec %
		<i>(unaudited) RMB</i>	<i>(unaudited) US\$</i>	
Net revenues:	243,245	316,920	46,429	30.3%
Gross profit	221,504	291,684	42,732	31.7%
<i>Gross profit margin</i>	<i>91.1%</i>	<i>92.0%</i>	<i>92.0%</i>	<i>0.9%</i>
Operating expenses	173,713	207,301	30,370	19.3%
Operating income	47,791	84,383	12,362	76.6%
<i>Operating margin</i>	<i>19.6%</i>	<i>26.6%</i>	<i>26.6%</i>	<i>7.0%</i>
Net income attributable to the equity holders of the parent	39,542	83,435	12,224	111.0%
Net income per ADS attributable to the equity holders of the parent <i>Basic and diluted</i>	1.82	3.87	0.57	112.6%

Note: YoY changes are based on RMB values.

Please refer to "Reconciliation Tables of GAAP to Non-GAAP Figures" in the press release. Non-GAAP items for the three and twelve month periods ended December 31, 2009 have been revised to conform to the current year's presentation basis.



Highlights for Fourth Quarter 2009 (Non-GAAP)

<i>(Non-GAAP, expressed in millions, except per ADS data.)</i>	For the three months ended Dec 31, 2008 <i>(unaudited) RMB</i>	For the three months ended Dec 31, 2009		YoY Inc/dec %
		<i>(unaudited) RMB</i>	<i>(unaudited) US\$</i>	
Net revenues:	60,064	74,276	10,881	23.7%
Gross profit	54,552	68,221	9,994	25.0%
<i>Gross profit margin</i>	<i>90.8%</i>	<i>91.8%</i>	<i>91.8%</i>	<i>1.0%</i>
Operating expenses	48,492	54,739	8,020	12.9%
Operating income	6,060	13,482	1,974	122.5%
<i>Operating margin</i>	<i>10.1%</i>	<i>18.2%</i>	<i>18.1%</i>	<i>8.1%</i>
Net income attributable to the equity holders of the parent	11,287	14,457	2,117	28.0%
Net income per ADS attributable to the equity holders of the parent <i>Basic and diluted</i>	0.52	0.66	0.10	26.9%

Note: YoY changes are based on RMB values.

Please refer to "Reconciliation Tables of GAAP to Non-GAAP Figures" in the press release. Non-GAAP items for the three and twelve month periods ended December 31, 2009 have been revised to conform to the current year's presentation basis.



Financial Summary (Non-GAAP)

1Q-4Q 2009

Highlights For Full Year 2009 (Non-GAAP)

<i>(Non-GAAP, expressed in millions, except per ADS data.)</i>	For the full year ended Dec 31, 2008 <i>(audited) RMB</i>	For the full year ended Dec 31, 2009		YoY Inc/dec %
		<i>(unaudited) RMB</i>	<i>(unaudited) US\$</i>	
Net revenues:	243,245	316,920	46,429	30.3%
Gross profit	221,874	292,240	42,813	31.7%
<i>Gross profit margin</i>	91.2%	92.2%	92.2%	1.0%
Operating expenses	162,147	201,298	29,491	24.1%
Operating income	59,727	90,942	13,322	52.3%
<i>Operating margin</i>	24.6%	28.7%	28.7%	4.1%
Net income attributable to the equity holders of the parent	75,013	90,257	13,222	20.3%
Net income per ADS attributable to the equity holders of the parent <i>Basic and diluted</i>	3.46	4.18	0.61	20.8%

Note: YoY changes are based on RMB values.

Please refer to "Reconciliation Tables of GAAP to Non-GAAP Figures" in the press release. Non-GAAP items for the three and twelve month periods ended December 31, 2009 have been revised to conform to the current year's presentation basis.



Healthy Cash Flow and Solid Balance Sheet

CASH FLOW			
	Full year ended Dec 31, 2008	Full year ended Dec 31, 2009	
<i>(expressed in thousands)</i>	(audited) RMB	(unaudited) RMB	(unaudited) US\$
Operating cash flow	60,468	87,718	12,852
BALANCE SHEET			
	As of Dec 31, 2008	As of Dec 31, 2009	
<i>(expressed in thousands)</i>	(audited) RMB	(unaudited) RMB	(unaudited) US\$
Cash, cash equivalents	439,237	272,767	38,469
Restricted cash	-	9,300	1,362
Time deposits	293,809	468,451	68,628
Current assets	824,612	852,634	124,911
Total assets	952,918	1,053,461	154,332
Current liabilities	28,899	38,445	5,632
Total liabilities	32,523	41,223	6,039
Noncontrolling interests	-	-	-
Shareholders' equity	920,395	1,012,238	148,293
Total liability and shareholders' equity	952,918	1,053,461	154,332



www.3sbio.com

Cherish Life

Create Life

Care for Life



2009 Fourth Quarter

OPERATIONAL AND STRATEGIC HIGHLIGHTS




EPIAO – Growing the Market Leader

4Q09 EPIAO Highlights

- ❖ RMB 45.5 million (US\$6.7 million) in sales for fourth quarter 2009: 15.8% increase over fourth quarter 2008
- ❖ Remains leading revenue contributor : 61.3% of total sales in fourth quarter 2009

EPIAO Quarterly Revenue Trends

USD Millions






TPIAO – Rapid Market Acceptance

4Q09 TPIAO Highlights

- ❖ RMB 20.9 million (US\$3.1 million) in sales for fourth quarter 2009: 27.4 % increase over fourth quarter 2008
- ❖ Remains the second largest revenue contributor: 28.1 % of total sales in fourth quarter 2009

TPIAO Quarterly Revenue Trends

USD Millions





R&D Pipeline – Innovative Products, Clear Market Focus

Product Name	Indication(s)	Preclinical	Phase I	Phase II	Phase III	Submitted for SFDA Approval
High Dose EPIAO	Anemia associated with chemotherapy	→				
TPIAO	ITP Label Extension	→				
Nuleusin	Renal cell carcinoma Metastatic melanoma	→				
Feraheme	Anemia associated with Chronic Kidney Disease	→				
Nephoxil	Hyperphosphatemia	→				
NuPIAO (2ndGen EPO)	Anemia associated with renal failure or chemotherapy, peri- operative blood cell mobilization	→				
Anti-TNF Rab (SSS07)	Rheumatoid arthritis	→				
HPV vaccine (SSS08)	Cervical cancer	→				



Pursuing Business Development and M&A Opportunities to Complement Organic Growth

Strategy and Value Driven Business Development Approach

- ❖ Focused Business Development and Licensing
 - Therapeutics that complement our existing product portfolio and commercial expertise in Oncology, Nephrology and Autoimmune diseases
 - Marketed products or R&D projects beyond proof of concept stage
 - Differentiated therapeutics with distinctive commercial competitiveness
 - Globally
- ❖ Opportunistic Value Driven M&A approach
 - Financially sound companies to enhance top and bottom line growth
 - Synergistic products marketed or at advanced stage of clinical trials to expand product portfolio
 - R&D capabilities that can further enrich our current product pipeline
 - Corporations that adhere to high standards of corporate governance
 - Within China



www.3sbio.com

Cherish Life

Create Life

Care for Life



2009 Fourth Quarter

FUTURE INITIATIVES AND STRATEGIES



Focused Strategies to Drive Growth and Profitability in 2010





www.3sbio.com

Cherish Life

Create Life

Care for Life



Appendix




Key Revenue Drivers – EPIAO & TPIAO

Healthy End-Market Fundamentals Drive Growth


- ❖ EPIAO – sustainable growth year-over-year driven by oncology and dialysis market penetration and expansion
- ❖ TPIAO – rapid growth demonstrates physician acceptance of product
- ❖ Continued product growth highlights underlying strength of therapeutic markets

2009 Full Year



■ EPIAO ■ TPIAO ■ Intefen ■ Inleusin
■ Iron ■ Export ■ Others

2008 Full Year




■ EPIAO ■ TPIAO ■ Intefen ■ Inleusin
■ Iron ■ Export ■ Others



EPO China Market Growth

Chinese Total EPO Market in Volume and Sales (1999-2008)



Source: IMS Health

www.3sbio.com








EPIAO – Growing the Market Leader

- ❖ EPIAO has consistently outperformed the competition
- ❖ 41.0% market share by value and 29.4% by unit volume in 3Q2009

EPO Market Share (Volume)



EPO Market Share (Value)






Source: IMS Health



EPIAO – Accelerated Growth in Volume & Value

Chinese EPO Market Volume and Value (1999-2008)



Source: IMS Health